ON-Going Care in mCRC: Strategies for Long-Term Disease Control with Bevacizumab Combination Therapy (IASGO 2026) - Sep 23, 2026 - Abstract #LS01-2; Pres time: Sep 9, 2026; 12:00 PM - 01:00 PM; "In refractory mCRC, the SUNLIGHT trial showed that trifluridinetipiracil plus bevacizumab improved overall and progression-free survival compared with trifluridinetipiracil alone. Regorafenib and fruquintinib remain additional later-line options for appropriate patients.Tolerability, marrow reserve, organ function, performance status, and patient preference should guidesequencing. A case with prolonged disease control across bevacizumab-FOLFIRI, surgery, bevacizumab-FOLFOX,radiotherapy, and later-line therapy demonstrates the value of coordinated sequential decisions.Korean post-marketing experience with the SB8 bevacizumab biosimilar (ONBEVZI) providessupportive real-world information and may help expand access. The goal is not simply to maximize oneregimen's duration, but to preserve function and deliver active therapy across the entire disease course."
Combination therapy • Colorectal Cancer • Solid Tumor • BRAF
|